Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Study of Erlotinib Alone Versus Erlotinib Plus Bevacizumab for Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations
Conditions
Interventions
Erlotinib plus Bevacizumab
Erlotinib
Locations
1
South Korea
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Start Date
November 1, 2016
Primary Completion Date
December 31, 2021
Completion Date
July 20, 2023
Last Updated
April 6, 2022
NCT04027647
NCT04105153
NCT03402464
NCT01665417
NCT02103257
NCT02194556
Lead Sponsor
National Cancer Center, Korea
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions